Affimed N.V. - ADR Peer Comparison
$0.08
$-0.11
(-58.07%)
As on 18-Jun-2025 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Edit
| Affimed N.V. - ADR | Pharvaris BV (PHVS) | CureVac NV (CVAC) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
3 | 2,480 | 1,049 | 323 | 329 |
Revenue (€ Mln) |
1 | -- | 511 | 19 | 0 |
Net Profit (€ Mln) |
-69.97 | -171.57 | 193.64 | -42.32 | -39.14 |
Net Margin (%) |
-7,978.34 | -- | 37.93 | -228.38 | 387,532.08 |
RoE (%) |
-241.87 | -59.98 | 25.51 | -65.71 | -41.72 |
Price to Earnings |
-- | -- | 6.96 | -- | -- |
Price-To-Book |
0.06 | 7.40 | 1.03 | 3.51 | 1.95 |
Cashflow (€ Mln)
| Affimed N.V. - ADR | Pharvaris BV (PHVS) | CureVac NV (CVAC) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-110.27 | -93.05 | -267.89 | 21.55 | -37.81 |
|
Cash Flow from Investing Activities
|
-- | -0.09 | -55.20 | 4.28 | -17.70 |
|
Cash from Financing Activities
|
-6.22 | 325.39 | 230.89 | -2.28 | 52.99 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Affimed N.V. - ADR | Pharvaris BV (PHVS) | CureVac NV (CVAC) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-85.34 | -37.78 | -45.88 | -34.60 | -44.12 |
|
ROE (%)
|
-241.87 | -37.83 | -49.55 | -47.95 | -44.69 |
|
ROA (%)
|
-67.90 | -35.62 | -31.56 | -16.78 | -38.33 |
|
EBIT Margin (%)
|
-7,823.03 | -- | -- | -- | -- |
|
Net Margin (%)
|
-7,978.34 | -- | -483.96 | -431.67 | -67,630.69 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Affimed N.V. - ADR | Pharvaris BV (PHVS) | CureVac NV (CVAC) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-95.39 | -- | -0.20 | 0.81 | -- |
|
EBIT Growth (%)
|
39.98 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
42.86 | -32.15 | -4.47 | 56.35 | -44.71 |
|
EPS Growth (%)
|
-- | 0.15 | 0.12 | 0.57 | -0.09 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Affimed N.V. - ADR | Pharvaris BV (PHVS) | CureVac NV (CVAC) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -14.54 | -3.62 | -5.52 | -2.25 |
|
Price / Book Value
|
-- | 3.82 | 1.82 | 3.40 | 0.94 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.52 | -10.80 | -2.48 | -1.90 | -0.17 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Affimed N.V. - ADR | Pharvaris BV (PHVS) | CureVac NV (CVAC) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.13 | 0.00 | 0.08 | 0.48 | 0.01 |
|
Short term debt to equity ratio
|
0.40 | 0.00 | 0.01 | 0.04 | 0.00 |
|
Current Ratio
|
1.93 | 27.25 | 2.57 | 3.54 | 6.50 |
|
Quick Ratio
|
1.93 | 27.27 | 2.43 | 3.54 | 5.82 |
|
Interest Coverage
|
-50.52 | -4,977.62 | -103.28 | -22.12 | -1,196.58 |
Operating Efficiency Ratios
| Affimed N.V. - ADR | Pharvaris BV (PHVS) | CureVac NV (CVAC) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
518.02 | -- | 73.50 | 21.50 | 6,009.87 |
|
Asset Turnover
|
0.01 | 0.00 | 0.07 | 0.04 | 0.00 |
|
Receivable days
|
177.09 | -- | 164.80 | 1,751.84 | 15,121.01 |
|
Inventory Days
|
-- | 2,694.23 | 71.65 | 9.39 | 3,900.42 |
|
Payable days
|
-- | 6,434.88 | 170.75 | 2,900.45 | 3,462.07 |
|
Cash Conversion Cycle
|
-- | -- | 65.70 | -1,139.22 | 15,559.36 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
